The OncLive Mantle Cell Lymphoma condition center page is a comprehensive resource for clinical news and expert insights on mantle cell lymphoma treatment. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, therapeutic advances, and ongoing research in mantle cell lymphoma.
May 2nd 2024
Acalabrutinib plus bendamustine and rituximab (BR) led to a statistically significant improvement in PFS vs BR for treatment-naive mantle cell lymphoma.
Patient, Provider, and Caregiver Connection: Addressing Pediatric and AYA Patient Concerns While Managing Hodgkin Lymphoma
View More
Patient, Provider, and Caregiver Connection™: Individualizing Care for Patients with Schizophrenia—Understanding Patient Challenges and the Role of Innovative Treatment
View More
Improving Outcomes in Autoimmune Hemolytic Anemias at the Intersection Between Hematology and Oncology Care
View More
Everything You Need to Know About PARP Inhibitor Combinations in Prostate Cancer Care: Why? For Whom? And When?
View More
Live “Hot Seat”: Experts Face Your Hot-Button Questions on Maximizing PARP Inhibitors in Patients With CRPC
View More
Multidisciplinary Management of TNBC: Immunotherapy, PARP, TROP2, Oh My!
View More
Community Practice Connections™: The Advent of TROP2-Targeted Treatment Approaches in HR+/HER2- Breast Cancer
View More
Community Practice Connections™: Controversies and Conversations About HER2- Expressing Breast Cancer…Advances in Management of HER2-Low to -Positive Disease
View More
Show Me the Data™: Do We Have Sea Change for Novel Approaches in HR+/HER2- Breast Cancer? CDK, PI3K/AKT, ADC, and Next-Gen SERD Strategies Assessed
View More
B-Cell Tumor Board: Rendering Real World Personalized Treatment Plans in CLL/SLL and MCL Through the Lens of Emerging BTKi Evidence
View More
Cancer Summaries and Commentaries™: Clinical Updates from Chicago in Breast Cancer
View More
8th Annual School of Nursing Oncology™
August 10, 2024
Register Now!
Cancer Summaries and Commentaries™: Clinical Updates in RCC from Chicago
View More
Applying New Evidence in Multiple Myeloma Care from Frontline to R/R Disease
View More
Medical Crossfire®: How Do Clinicians Integrate the Latest Evidence in Treating Ovarian Cancer to Personalize Care?
View More
Medical Crossfire®: How Does Recent Evidence on PARP Inhibitors and Combinations Inform Treatment Planning for Prostate Cancer Now and In the Future?
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
How CEACAM5 Expression Can Be Measured and Leveraged in NSCLC Care: Current Developments & Future Therapeutic Opportunities
View More
Medical Crossfire®: Where Are We in the World of ADCs? From HER2 to CEACAM5, TROP2, HER3, CDH6, B7H3, c-MET and Beyond!
View More
Community Oncology Connections™: Overcoming Barriers to Testing, Trial Access, and Equitable Care in Cancer
View More
Medical Crossfire: How Has Iron Supplementation Altered Treatment Planning for Patients with Cancer-Related Anemia?
View More
Translating New Evidence into Treatment Algorithms from Frontline to R/R Multiple Myeloma: How the Experts Think & Treat
View More
Dialogues With the Surgeon on Integration of Systemic Therapies in Perioperative Settings for NSCLC: Looking at EGFR, ALK, IO, and Beyond…
View More
The Next Wave in Biliary Tract Cancers: Leveraging Immunogenicity to Optimize Patient Outcomes in an Evolving Treatment Landscape
View More
The Evolving Tool Box in Advanced HR+/HER2– Breast Cancer: What You Need to Know About Next-Generation SERDs, PI3K/AKT, ADCs, CDK4/6 and Beyond…
View More
Medical Crossfire®: The Experts Bridge Recent Data in Chronic Lymphocytic Leukemia With Real-World Sequencing Questions
View More
Community Practice Connections™: Pre-Conference Workshop on Immune Cell-Based Therapy
View More
Coffee Talk™: Navigating the Impact of HER2/3, TROP2, and PARP from Early Stage to Advanced Breast Cancer Care
View More
Rituximab Maintenance Therapy Continues to Provide Remission Benefit in MCL
July 20th 2022Brad S. Kahl, MD, explains the evolution of mantle cell lymphoma treatment over the past decade and lays out the trajectory for future therapies, including the potential benefits of lenalidomide in the maintenance setting.
Ibrutinib Plus Bendamustine and Rituximab Prolongs PFS Benefit in Newly Diagnosed MCL
June 21st 2022Michael Wang, MD, discusses the innovative design of the SHINE trial, notes the importance of developing improved treatments for older patient populations, and highlights significant progression-free survival and safety data from the study.
Ibrutinib Plus Bendamustine and Rituximab Shows PFS Benefit in Older Patients with MCL
June 3rd 2022Ibrutinib in combination with bendamustine and rituximab with rituximab maintenance elicited a significant improvement in progression-free survival compared with standard chemoimmunotherapy in older patients with mantle cell lymphoma.
Frontline BTK Inhibitors Improve OS in Real-World Patients with MCL
The use of BTK inhibitors as a frontline treatment improved overall survival vs their deployment in subsequent lines of therapy in patients with mantle cell lymphoma, according to a real-world study (IRB-300004501) published in Blood Advances.
Zanubrutinib Approved in Uruguay for MCL, MZL, and Waldenström Macroglobulinemia
The BTK inhibitor zanubrutinib has been approved in Uruguay for the treatment of adult patients with previously treated mantle cell lymphoma, relapsed or refractory marginal zone lymphoma, and Waldenström macroglobulinemia.
Emerging Chemotherapy-Free Approaches Raise Sequencing Questions in MCL Management
Martin F. Dietrich, MD, PhD, highlights recent updates in mantle cell lymphoma treatment, explains how new developments have raised sequencing questions, and projects where future research efforts will focus.
Ibrutinib-Based Combination Therapy Displays Superior Efficacy Vs Monotherapy in MCL
May 9th 2022Ibrutinib-based combination therapy demonstrated a higher overall response rate and longer progression-free survival compared with ibrutinib alone in patients with relapsed/refractory mantle cell lymphoma.
COVID-19 Mortality Rates Rise With Hospitalization and Rituximab Treatment in MCL
May 6th 2022The overall mortality rate for patients with mantle cell lymphoma who contract COVID-19 is high, and mortality rates rise significantly in patients who are hospitalized or enter intensive care units, according to findings from a retrospective study that were published in Hemasphere.
Rituximab Plus Bendamustine Proves Promising in Young Patients With MCL
May 5th 2022The combination of bendamustine and rituximab plus autologous stem cell transplantation and maintenance rituximab was shown to be an effective first-line treatment with comparable outcomes to R-CHOP/R-DHAP plus ASCT and observation in young patients with transplant-eligible mantle cell lymphoma.
European Approval Sought for Ibrutinib Plus Bendamustine/Rituximab for Previously Untreated MCL
A Type II variation application seeking the approval of a new indication for ibrutinib plus bendamustine and rituximab in adult patients with previously untreated mantle cell lymphoma who are not candidates for autologous stem cell transplant has been submitted to the European Medicines Agency.
Folding CAR T-cell Therapy Into Relapsed/Refractory MCL Treatment
March 9th 2022Treatment with the CD19-directed CAR T-cell therapy brexucabtagene autoleucel demonstrated significant activity, marked by high response rates and prolonged survival, in patients with relapsed mantle cell lymphoma in the pivotal ZUMA-2 trial.
Higher Doses of Ibrutinib/Venetoclax Not Linked With Higher Responses in Relapsed/Refractory MCL
The combination of ibrutinib given at 420 mg and venetoclax at 200 mg elicited an objective response rate of 93.8% in patients with relapsed/refractory mantle cell lymphoma, according to results of a phase 1 dose-finding study.
Frontline Ibrutinib/Rituximab Produced Meaningful Response Rates in Indolent MCL
The combination of ibrutinib plus rituximab generated a high rate of complete response and undetectable minimal residual disease when used in the frontline treatment of patients with indolent clinical forms of mantle cell lymphoma, allowing for treatment interruption in most responders.
Ibrutinib/Rituximab Followed by R-HCVAD Shows Activity, Safety in Younger Patients With MCL
Induction treatment with ibrutinib and rituximab was safe and active in patients with mantle cell lymphoma aged 65 years or younger, allowing for fewer cycles of subsequent chemotherapy with rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone thereby reducing toxicity.
Treatment Strategies for Relapsed/Refractory MCL Represent a Unique Challenge
February 8th 2022Despite the breakthroughs in the development of therapeutic regimens for patients with mantle cell lymphoma, variability in treatment pathways presents a unique hurdle in determining the appropriate course of care following disease progression.
Incyte Withdraws NDA for Parsaclisib in Relapsed/Refractory Follicular Lymphoma, MZL, MCL
The global biopharmaceutical company Incyte has decided to withdraw the new drug application for parsaclisib for the treatment of patients with relapsed or refractory follicular lymphoma, marginal zone lymphoma, and mantle cell lymphoma.